Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202760 · ClinicalTrials.gov registry record · Phase 3
A Rheumatoid Arthritis Study in Participants
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,004
- Enrollment target
NCT01202760 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,004 participants.
The verdict
NCT01202760, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,004 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. This study is comprised of 2 periods: Period 1 - 24-week blinded treatment Period 2 - 48-week post-treatment follow-up
Interventions
- DRUG Placebo
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,004 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202760
The ClinicalTrials.gov registry entry for NCT01202760 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,004 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01202760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202760 about?
NCT01202760 is a clinical study titled "A Rheumatoid Arthritis Study in Participants". The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. This study is comprised of 2 periods: Period 1 - 24-week blinded treatment Period 2 - 4...
What is the current status of trial NCT01202760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,004 participants. The study started on 2011-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01202760?
The interventions under investigation include: Placebo (DRUG), LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01202760?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.